Sunshine Biopharma Inc. (SBFM): Price and Financial Metrics


Sunshine Biopharma Inc. (SBFM): $0.73

0.00 (0.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SBFM POWR Grades

  • Growth is the dimension where SBFM ranks best; there it ranks ahead of 80.93% of US stocks.
  • The strongest trend for SBFM is in Value, which has been heading up over the past 154 days.
  • SBFM ranks lowest in Stability; there it ranks in the 1st percentile.

SBFM Stock Summary

  • The ratio of debt to operating expenses for SUNSHINE BIOPHARMA INC is higher than it is for about just 0.44% of US stocks.
  • With a year-over-year growth in debt of -100%, SUNSHINE BIOPHARMA INC's debt growth rate surpasses merely 0% of about US stocks.
  • SUNSHINE BIOPHARMA INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -236%, greater than the shareholder yield of only 2.78% of stocks in our set.
  • Stocks that are quantitatively similar to SBFM, based on their financial statements, market capitalization, and price volatility, are VOXX, ITRN, NBRV, UG, and RDY.
  • To dig deeper into the stock's financial statements, go to SBFM's page on browse-edgar?action=getcompany&CIK=0001402328.

SBFM Valuation Summary

  • In comparison to the median Healthcare stock, SBFM's price/sales ratio is 661.7% higher, now standing at 35.8.
  • Over the past 163 months, SBFM's price/earnings ratio has gone up 373.1.

Below are key valuation metrics over time for SBFM.

Stock Date P/S P/B P/E EV/EBIT
SBFM 2023-03-24 35.8 0.4 -6.9 9.1
SBFM 2023-03-23 36.3 0.4 -6.9 9.1
SBFM 2023-03-22 36.5 0.4 -7.0 9.0
SBFM 2023-03-21 36.9 0.4 -7.1 8.9
SBFM 2023-03-20 35.8 0.4 -6.9 9.1
SBFM 2023-03-17 38.5 0.5 -7.4 8.6

SBFM Growth Metrics

    The year over year revenue growth rate now stands at 209.88%.
  • Its 3 year net cashflow from operations growth rate is now at -390.39%.
  • Its 2 year net cashflow from operations growth rate is now at -868.33%.
Over the past 30 months, SBFM's revenue has gone up $458,861.

The table below shows SBFM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.490878 -3.313859 -2.565009
2022-06-30 0.408446 -2.790931 -5.147373
2022-03-31 0.311013 -2.835981 -7.487555
2021-12-31 0.228426 -1.829128 -12.43645
2021-09-30 0.171321 -1.940687 -14.18736
2021-09-30 0.171321 -1.940687 -14.18736

SBFM Stock Price Chart Interactive Chart >

Price chart for SBFM

SBFM Price/Volume Stats

Current price $0.73 52-week high $9.87
Prev. close $0.73 52-week low $0.62
Day low $0.69 Volume 173,400
Day high $0.74 Avg. volume 214,376
50-day MA $0.93 Dividend yield N/A
200-day MA $0.95 Market Cap 16.51M

Sunshine Biopharma Inc. (SBFM) Company Bio


Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. Its products include treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Pointe-Claire, Canada.


SBFM Latest News Stream


Event/Time News Detail
Loading, please wait...

SBFM Latest Social Stream


Loading social stream, please wait...

View Full SBFM Social Stream

Latest SBFM News From Around the Web

Below are the latest news stories about SUNSHINE BIOPHARMA INC that investors may wish to consider to help them evaluate SBFM as an investment opportunity.

Sunshine Biopharma Signs Exclusive Worldwide License With University of Arizona For PLpro-Based Covid-19 Treatment

MONTREAL, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the signing of an exclusive worldwide license agreement (the “License Agreement”) with the University of Arizona. The License Agreement grants Sunshine Biopharma exclusive worldwide rights for all of the University of Arizona and University of Illinois Chica

Yahoo | February 28, 2023

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound

MONTREAL, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the signing of a research agreement with Sir Mortimer B. Davis Jewish General Hospital, a McGill University Health Center hospital located in Montreal, Quebec, Canada. The research effort will be focused on advancing the development of Sunshine Biopharma’s A

Yahoo | February 10, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's the final day of trading this week and we're checking in on the biggest pre-market stock movers for Friday morning!

William White on InvestorPlace | January 20, 2023

Sunshine Biopharma Announces Share Repurchase Program

MONTREAL, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced its board of directors has authorized a share repurchase program to acquire up to $2 million of the Company’s common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with

Yahoo | January 19, 2023

Insider Buying: Sunshine Biopharma Inc. (NASDAQ: SBFM) Chief Financial Officer Purchases Shares

By Jad Malaeb, Benzinga

Yahoo | December 27, 2022

Read More 'SBFM' Stories Here

SBFM Price Returns

1-mo -19.79%
3-mo 14.06%
6-mo -9.88%
1-year -68.12%
3-year -39.17%
5-year -99.88%
YTD 14.06%
2022 -94.53%
2021 272.61%
2020 57.00%
2019 -96.88%
2018 -93.28%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8111 seconds.